Hydroxymethylfurfural

Small moleculeexperimental

Clinical trial activity

3 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2012 (NCT01597401)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2013

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • 5-hm-2-f cpd
  • 5-hmf cpd
  • 5-(hydroxymethyl)-2-furaldehyde
  • 5-(hydroxymethyl)-2-furaldehyde
  • 5-hydroxymethyl-2-furaldehyde
  • 5-hydroxymethyl-2-furfural
  • 5-hydroxymethylfuraldehyde
  • 5-hydroxymethylfurfural
  • 5-(hydroxymethyl)furfural
  • 5-hydroxymethyl furfural
  • 5-hydroxymethylfurfuraldehyde
  • aes-103
  • aes-103
  • aes-103
  • hydroxymethylfurfural

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01987908Phase 2Oct 1, 2013Baxalta
NCT01871142Phase 1/Phase 2 (Phase 2)Mar 1, 2013AesRx, Colorado State University
NCT01597401Phase 1May 1, 2012Baxalta, Cato Research, National Cheng Kung University, National Heart, Lung, and Blood Institute (NHLBI), Nuventra Pharma Sciences, Inc., Quotient, Ricerca Biosciences LLC, SAIC-Frederick, Inc.
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BaxaltaFor profit2222012
AesRxFor profit1012013
Cato ResearchFor profit1012012
Colorado State UniversityAcademic/Hospital1112013
National Cheng Kung UniversityAcademic/Hospital1012012
National Heart, Lung, and Blood Institute (NHLBI)Government1012012
Nuventra Pharma Sciences, Inc.For profit1012012
QuotientFor profit1012012
Ricerca Biosciences LLCFor profit1012012
SAIC-Frederick, Inc.For profit1012012
10 organizations
Page 1 / 1